JP2021513328A5 - - Google Patents
Info
- Publication number
- JP2021513328A5 JP2021513328A5 JP2020541758A JP2020541758A JP2021513328A5 JP 2021513328 A5 JP2021513328 A5 JP 2021513328A5 JP 2020541758 A JP2020541758 A JP 2020541758A JP 2020541758 A JP2020541758 A JP 2020541758A JP 2021513328 A5 JP2021513328 A5 JP 2021513328A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- disease
- ms4a6a
- group
- disorder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023095282A JP2023113896A (ja) | 2018-01-31 | 2023-06-09 | 抗ｍｓ４ａ６ａ抗体及びその使用方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862624578P | 2018-01-31 | 2018-01-31 | |
| US62/624,578 | 2018-01-31 | ||
| US201862646846P | 2018-03-22 | 2018-03-22 | |
| US62/646,846 | 2018-03-22 | ||
| PCT/US2019/016141 WO2019152706A1 (en) | 2018-01-31 | 2019-01-31 | Anti-ms4a6a antibodies and methods of use thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023095282A Division JP2023113896A (ja) | 2018-01-31 | 2023-06-09 | 抗ｍｓ４ａ６ａ抗体及びその使用方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021513328A JP2021513328A (ja) | 2021-05-27 |
| JP2021513328A5 true JP2021513328A5 (enExample) | 2022-02-07 |
Family
ID=67479397
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020541758A Pending JP2021513328A (ja) | 2018-01-31 | 2019-01-31 | 抗ｍｓ４ａ６ａ抗体及びその使用方法 |
| JP2023095282A Pending JP2023113896A (ja) | 2018-01-31 | 2023-06-09 | 抗ｍｓ４ａ６ａ抗体及びその使用方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023095282A Pending JP2023113896A (ja) | 2018-01-31 | 2023-06-09 | 抗ｍｓ４ａ６ａ抗体及びその使用方法 |
Country Status (5)
| Country | Link |
|---|---|
| US (2) | US20210122817A1 (enExample) |
| EP (1) | EP3746484A4 (enExample) |
| JP (2) | JP2021513328A (enExample) |
| CN (1) | CN112204050B (enExample) |
| WO (1) | WO2019152706A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
| WO2019152706A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a6a antibodies and methods of use thereof |
| CA3145885A1 (en) | 2019-07-31 | 2021-02-04 | Jeonghoon Sun | Anti-ms4a4a antibodies and methods of use thereof |
| CN115029383B (zh) * | 2022-04-21 | 2024-02-20 | 苏天生命科技(苏州)有限公司 | Ms4a3蛋白在调控红细胞成熟中的应用 |
| CN116219009B (zh) * | 2022-10-19 | 2024-10-01 | 杭州师范大学 | 小胶质细胞特异性表达的ms4a6a在胶质母细胞瘤治疗或预后评估试剂盒上的应用 |
| WO2025096087A1 (en) * | 2023-10-30 | 2025-05-08 | Regeneron Pharmaceuticals, Inc. | Treatment of myeloid cell dysfunction with membrane spanning 4-domains a6a (ms4a6a) inhibitors |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002251692A1 (en) | 2000-12-08 | 2002-08-19 | Duke University | Identification of novel ms4a gene family members expressed by hematopoietic cells |
| GB0125338D0 (en) | 2001-10-22 | 2001-12-12 | Isis Innovation | Process for reducing immunogenic reactions using selective TH1 cell binding antibodies |
| GB0324888D0 (en) | 2003-10-24 | 2003-11-26 | Novartis Ag | Organic compounds |
| JP2008506637A (ja) * | 2004-06-14 | 2008-03-06 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・ユニバーシティ・オブ・イリノイ | 胎児起源の細胞に対する抗体 |
| CN101001879A (zh) | 2004-06-14 | 2007-07-18 | 伊利诺伊大学董事会 | 与胎儿而非成体cd34+/cd36+细胞结合的抗体 |
| GB0624500D0 (en) | 2006-12-07 | 2007-01-17 | Istituto Superiore Di Sanito | A novel passive vaccine for candida infections |
| EP2108701A1 (en) | 2008-04-10 | 2009-10-14 | Ganymed Pharmaceuticals AG | Methods involving MS4A12 and agents targeting MS4A12 for therapy, diagnosis and testing |
| EP2390349A1 (en) * | 2010-05-25 | 2011-11-30 | Sanofi | Methods and uses relating to the identification of compound involved in pain as well as methods of diagnosing algesia |
| CN104774264B (zh) * | 2014-01-15 | 2018-09-14 | 上海易乐生物技术有限公司 | 抗人proBDNF单克隆抗体及其在疼痛中的作用 |
| CA2874083C (en) | 2014-12-05 | 2024-01-02 | Universite Laval | Tdp-43-binding polypeptides useful for the treatment of neurodegenerative diseases |
| US20190321443A1 (en) * | 2016-02-16 | 2019-10-24 | President And Fellows Of Harvard College | Modulators of MS4A activity |
| CN105759057A (zh) * | 2016-04-12 | 2016-07-13 | 上海凯璟生物科技有限公司 | 一种检测阿尔兹海默综合症ms4a6a的干式免疫荧光试剂盒和制备方法 |
| CN105969901B (zh) * | 2016-07-27 | 2019-10-11 | 北京泱深生物信息技术有限公司 | Ms4a6a作为多发性骨髓瘤诊治标志物的用途 |
| US11472874B2 (en) | 2018-01-31 | 2022-10-18 | Alector Llc | Anti-MS4A4A antibodies and methods of use thereof |
| WO2019152706A1 (en) | 2018-01-31 | 2019-08-08 | Alector Llc | Anti-ms4a6a antibodies and methods of use thereof |
| MA54880A (fr) | 2019-02-01 | 2021-12-08 | Avrobio Inc | Compositions et procédés de traitement de troubles neurocognitifs |
| CA3145885A1 (en) | 2019-07-31 | 2021-02-04 | Jeonghoon Sun | Anti-ms4a4a antibodies and methods of use thereof |
| KR20220084095A (ko) | 2019-10-22 | 2022-06-21 | 바이오젠 엠에이 인코포레이티드 | 알츠하이머병의 치료를 위한 항-베타-아밀로이드 항체 |
| WO2024086796A1 (en) | 2022-10-20 | 2024-04-25 | Alector Llc | Anti-ms4a4a antibodies with amyloid-beta therapies |
-
2019
- 2019-01-31 WO PCT/US2019/016141 patent/WO2019152706A1/en not_active Ceased
- 2019-01-31 US US16/965,675 patent/US20210122817A1/en not_active Abandoned
- 2019-01-31 JP JP2020541758A patent/JP2021513328A/ja active Pending
- 2019-01-31 CN CN201980018630.2A patent/CN112204050B/zh active Active
- 2019-01-31 EP EP19747384.6A patent/EP3746484A4/en active Pending
-
2022
- 2022-04-18 US US17/722,624 patent/US12215149B2/en active Active
-
2023
- 2023-06-09 JP JP2023095282A patent/JP2023113896A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021513329A5 (enExample) | ||
| JP2021513328A5 (enExample) | ||
| JP2020533948A5 (enExample) | ||
| HRP20230675T1 (hr) | Anti-trem2 protutijela i postupci njihove uporabe | |
| JP2022542964A5 (enExample) | ||
| JP2020532947A5 (enExample) | ||
| JP6844719B2 (ja) | 二重特異性抗体 | |
| JP2017523814A5 (enExample) | ||
| JP2021530960A5 (enExample) | ||
| US20170145078A1 (en) | Engineered heterodimeric protein domains | |
| JP7476997B2 (ja) | 二重特異性抗体 | |
| JP2020531043A (ja) | 抗４−１ｂｂ抗体とその作製及び使用方法 | |
| JP2022525478A5 (enExample) | ||
| JP2021529520A5 (enExample) | ||
| WO2020102233A1 (en) | Bispecific antibodies for activation of immune cells | |
| JP2021516951A5 (enExample) | ||
| JP2021531027A5 (enExample) | ||
| JP7688805B2 (ja) | 二重特異性抗体 | |
| JP2018502068A5 (enExample) | ||
| US20250043001A1 (en) | Anti-cd28 compositions | |
| JP7574692B2 (ja) | 二重特異性抗体 | |
| JP2024541476A5 (enExample) | ||
| JP2012506237A (ja) | Ｄｃ−ｓｉｇｎに対する結合特異性をもつリガンド | |
| US20250122299A1 (en) | ANTI-CD20 x ANTI-CD28 COMBINATION THERAPIES | |
| US20250084186A1 (en) | Anti-cd28 x anti-enpp3 antibodies |